Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
|
|
- Joleen Reynolds
- 5 years ago
- Views:
Transcription
1 Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
2 Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA <1% MET <1% MEK <1% NRAS <1% Unknown 56% FGFR1 amp 20% PIK3CA 10% PTEN 10% DDR2 4% Carcinoid Large Cell Large Cell Neuroendocrine 5% Unknown 90% PIK3CA amp 10% Lung Cancer Consortium ASCO 2011; Perez-Moreno Mountain, et al. CCR Chest
3 Selecting Targeted Drugs in Lung Adenocarcinoma 0.69 [95%CI, ], P =.006 Over 64% of lung ADK have an actionable driver oncogene Mark G. Kris,et al, JAMA 2014
4 EGFR mutations in lung cancer ACTIVATING MUTATIONS 10-14% white 30-40% asian * Most frequent Sharma SV, et al. Nat Rev Cancer 2007;7; Sharma SV, et al. Nat Rev Cancer 2007;7:169 81
5 EGFR mutations are oncogenic in vitro & in vivo Sharma SV, et al. Nat Rev Cancer 2007;7; Greulich H, et al. PLoS 2005 ; Hongbin Ji, et al. Cancer Cell 2006
6 EGFR mutations are sensitive to TKIs Paez Science 2004; Lynch NEJM 2004; Pao PNAS 2004
7 Efficacy of 1 st & 2 nd Generation TKIs in First Line STUDY EGFR TKI N RR (%) PFS (mo) OS (mo) Ref IPASS Gefitinib vs vs 6.3* 21.6 vs 21.9 Fukuoka, 2011 Erlotinib, Gefitinib, Afatinib, approved First-Signal Gefitinib vs vs vs 25.6 Han, 2012 WJTOG3405 Gefitinib vs vs 6.3* 36 vs 39 Yoshioka, 2014 Phase III TKI vs TKI : ARCHER 1050 (NCT ): phase III NEJ002 Gefitinib vs vs 5.4* 27.7 vs 26.6 Inoue, 2013 dacomitinib vs gefitinib, final accrual Febr 2015 OPTIMAL Erlotinib vs vs 4.6* 22.6 vs 28.8 Zhou, 2011 LUX-Lung 7 (NCT ): phase IIb EURTACC Erlotinib vs vs 5.2* 19.3 vs 19.5 Rosell, 2012 afatinib vs gefitinib, final accrual Sept 2013 ENSURE Erlotinib vs vs 5.5* NR Wu, 2013 LUX-LUNG 3 Afatinib vs vs 6.9* 31.6 vs 28.2 Sequist, 2013 LUX-LUNG 6 Afatinib vs vs 5.6* 23.6 vs 23.5 Wu, 2014
8 Del 19 Common mutations L858R Yang et al. Lancet Oncol 2015
9 Current treatment beyond TKI progression EGFR MUT FIRST LINE TKI 12 mo SECOND LINE QTP 6 mo THIRD LINE QTP 3-5 mo BSC 2 mo OS mo
10 Resistance Mechanisms for TKIs Pooled data from the 2 largest re-biopsy series after TKI-progression. Arcila, CCR 2011; Sequist et al. Sci Transl Med 2011
11 Strategies to overcome AR to TKIs Chong et al, Nature Medicine 2013
12 3 rd Generation T790M inhibitors TKIs spare EGFR WT Generation TKI EGFR wt H2073 EGFR m ELREA (Exon 19) T790M- PC-9 T790M+ PC-9 VanR EGFR m L858R (Exon 21) T790M- H3255 T790M+ H1975 FIRST Gefitinib Erlotinib SECOND Afatinib Dacomitinib THIRD AZD CO HM Data form Cross et al, Cancer Discov 2014; Walter et al, Cancer Discov 2013
13 Log tumour volume Log tumour volume Activity of AZD9291 in vitro & in vivo In vitro resistance to AZD9291 took significantly longer to emerge Sustained tumour shrinkage in tumour xenografts PC9 (EGFR exon 19 deletion) (cm 3) 0.01 Vehicle only BID Gefitinib 6.25 mg/kg QD AZD mg/kg QD AZD mg/kg QD Da ys H3255 (EGFR L858R) (cm 3) Vehicle only BID Gefitinib 6.25 mg/kg QD AZD mg/kg QD Afatinib 7.5 mg/kg QD Day s Eberlein et al. Proceedings of the 105th AACR 2014; abstract 1722.
14 Phase I dose escalation/expansion study design (AURA) Escalation Not preselected by T790M status Cohort 1 20 mg Cohort 2 40 mg Rolling six design Cohort 3 80 mg Cohort mg Cohort mg Expansion Enrolment by local testing followed by central laboratory confirmation (cobas EGFR Mutation Test) of T790M status or by central laboratory testing alone T790M+ T790M+ T790M- T790M+ T790M- 1st-line EGFRm+ * Biopsy # T790M+ T790M- 1st-line EGFRm+ * Biopsy # T790M+ Tablet ## Total 253 patients included Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
15 ORR in T790M+ patients (central test) 40 61% ORR (per RECIST) mg 40 mg 80 mg 160 mg 240 mg -100 Confirmed ORR in patients with T790M+ 61% (78/127; 95% CI 52, 70) DCR (CR+PR+SD) was 95% (121/127; 95% CI 90, 98) 20 mg 40 mg 80 mg 160 mg 240 mg N (127) ORR 50% 59% 70% 61% 50% Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
16 ORR in T790M- patients (central test) 40 21% ORR (per RECIST) mg 40 mg 80 mg 160 mg Confirmed ORR in patients with T790M- 21% (13/61; 95% CI 12, 34) DCR (CR+PR+SD) was 61% (37/61; 95% CI 47, 73) 20 mg 40 mg 80 mg 160 mg 240 mg N (127) ORR 67% 6% 17% 33% - Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
17 Probability of progression-free survival Progression-free survival in T790M+ (central test) T790M+ (95% CI) Preliminary median PFS = 9.6 months (95% CI 8.3, not reached) (30% maturity, 41/138 events) Patients at risk: T790M Study month Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
18 Probability of progression-free survival Progression-free survival in T790M- (central test) Preliminary median PFS = 2.8 months (95% CI 2.1, 4.3) (71% maturity, 44/62 events) T790M- (95% CI) Patients at risk: T790M Study month Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
19 All-causality AEs, all grades Patients with an AE, n (%) 20 mg N=21 40 mg N=58 80 mg N= mg N= mg N=21 Total N=253 AE by preferred term occurring in at least 10% of patients overall Diarrhoea 5 (24) 24 (41) 30 (33) 43 (68) 16 (76) 118 (47) Rash 5 (24) 13 (22) 29 (32) 40 (63) 15 (71) 102 (40) Fatigue 4 (19) 15 (26) 9 (10) 11 (17) 5 (24) 44 (17) Paronychia 2 (10) 5 (9) 11 (12) 18 (29) 6 (29) 42 (17) Hyperglycaemia 0 1 (2) 3 (3) 2 (3) 0 6 (2) QT prolongation 0 2 (3) 4 (4) 4 (6) 1 (5) 11 (4) Pneumonitis-like ev (2) 4 (6) 0 6 (2) - No dose-limiting toxicities at any dose - MTD not defined Pasi A. J. et al, NEJM 2015; ASCO 2014, abst 8009
20 Phase 1/2 of CO-1686 (Rociletinib) Key eligibility criteria Advanced or recurrent NSCLC with a documented activating EGFR mutation Prior treatment with EGFR-directed therapy Recent biopsy available or willing to undergo a new on-study biopsy Phase 2 only Disease progression while on treatment with EGFR-directed therapy T790M-positive biopsy at the time of entering study Phase 1 (Dose-escalation period) CO-1686 Treatment 21-day cycles; escalate to MTD Phase 2 (RP2D evaluation) TIGER X Expansion Cohorts 2 nd -line patients PD upon 1 immediate prior TKI >2 nd -line patients PD upon 2 TKI or chemotherapy 500 mg BID 625 mg BID 750 mg BID DoR, duration of response; ORR, objective response rate; FIH, first in human; MTD, maximum tolerated dose PK, pharmacokinetic; 20 RP2D, recommended Phase 2 dose L.V. Sequist, et al, NEJM 2015; Soria J.C, EORTC-AACR 2014
21 Best Response for Evaluable T790M+ Patients (N= 46) 59% ORR 93% DCR Median PFS 13.1 months* L.V. Sequist, et al, NEJM 2015; Soria J.C, EORTC-AACR 2014
22 Best Response for Evaluable T790M- Patients (N=17) 29% ORR (per RECIST) Median PFS 5.6 months L.V. Sequist, et al, NEJM 2015; Soria J.C, EORTC-AACR 2014
23 Signs of brain activity with CO-1686 (Rociletinib) 3 previous treatment lines Erlotinib immediately before CO mg BID 82% target lesion reduction at C2 CNS lesion response Baseline C2 L.V. Sequist, et al, NEJM 2015; Soria J.C, EORTC-AACR 2014
24 TIGER-X clinical dose group: AEs Treatment-related adverse events (all grades) seen in >10% of patients Adverse event Frequency, % Hyperglycemia 32 Diarrhea 25 Nausea 25 Reduced appetite 20 Fatigue 14 Muscle spasm 13 Vomiting 11 Grade 3/4 treatment-related adverse events seen in >5% of patients* Adverse event Frequency, % Hyperglycemia 14 *21% of patients had a grade 3/4 treatment-related adverse event and only hyperglycemia was observed in 5% of patients Rociletinib metabolite M502 is an inhibitor of IGF1R and accumulates in humans causing hyperglycemia Grade 3 QTc prolongation observed in 1 patient (625 mg BID) Pneumonitis observed in 4 patients (>200 patients, all doses, all genotypes) all quickly reversible 24 L.V. Sequist, et al, NEJM 2015; Soria J.C, EORTC-AACR 2014
25 Ongoing Trials with 3 rd Generation TKI AZD9291 -AURA- CO1686 -TIGER- The U.S. FDA has granted Breakthrough Therapy designation for Rociletinib and AZD9291 as treatment for mutant NSCLC in patients with the T790M mutation after progression on EGFRdirected therapy
26 Current treatment beyond TKI progression EGFR MUT/T790M+ FIRST LINE TKI 12 mo T790M INH mo SECOND LINE QTP 6 mo THIRD LINE QTP 3-5 mo BSC 2 mo OS 35 mo EGFR MUT/T790M- FIRST LINE TKI 12 mo????? SECOND LINE QTP 6 mo THIRD LINE QTP 3-5 mo BSC 2 mo
27 Final remarks Search for alternative options for EGFR MUT/T790M- : Selective c-met inhibitors (INC280, AZD6094) for c- Met AMP Best sequence 1 st /2 nd then 3 rd generation vs 3 rd generation TKI upfront Rebiopsies, when, where, how? cfdnat790m a good biomarker? Combos to delay resistance? TKIs plus c-met inhibitors or MEK inhibitors (selumetinib) or immune-checkpoint inhibitors?
28
29 EGFR mutations among ethnicity (Asian vs Caucasian) Barlesi, et al ASCO 2013; Johnson, et al. ASCO 2013; Sun et al. JCO 2010
30 Re-biopsies to asses for resistance mechanisms When? Local PD? Gradual PD? Dramatic PD? Where? How? High-FDG uptake: T790M+? - Percentage of tumour cells ( >50-80%)? - LCM or macrodisection? - More sensitive technics? Low-FDG uptake:t790m-?
31 Oncogenic Drivers in Lung Adenocarcinoma * ROS1 rearrangements in ~1% Over 64% of lung ADK have an actionable driver oncogene Mark Kris, P03.07, WLCC Sidney 2013
32 Third Generation T790M inhibitors AZD9291 CO1686 (Rociletinib) HM61713
33 IMPRESS Trial: Phase III continuation of Gefitinib beyond progression Advanced EGFR + NSCLC CR/PR> 4 mo or SD> 6 mo with fiirst line Gefitinib No prior chemotherapy RECIST progression to Gefitinib ECOG 0/1 1:1 Random N=265 EU & Asia Primary endpoint: PFS Secondary endpoints: OS, RR, DCR Symptoms & QoL Pemetrexed, IV, 500mg/m2 Cisplatin, IV, 75mg/m2 q 21 days x 6 cycles plus Gefitinib 250 mg QD Pemetrexed, IV, 500mg/m2 Cisplatin, IV, 75mg/m2 q 21 days x 6 cycles plus placebo Mok et al. Ann Oncol 2014; 25 (suppl 4): abstr LBA2_PR
34 Probability of PFS Probability of OS IMPRESS: Phase III continuation of Gefitinib beyond progression PFS OS (33% of events) Gefitinib (n=133) Placebo (n=132) PFS, mo HR a (95% CI) 0.86 (0.65, 1.13); p= Gefitinib (n=133) Placebo (n=132) Median OS, months HR a (95% CI) 1.62 (1.05, 2.52) p= Time of randomisation (months) Time of randomisation (months) Mok et al. Ann Oncol 2014; 25 (suppl 4): abstr LBA2_PR
35 Phase Ib of combined afatinib and cetuximab in EGFR MUT 29% ORR (per RECIST) Median PFS 4.7 months 126 pts ORR: T % and T790M - 25% MTD: afatinib 40 mg daily and cetuximab 500 mg/m 2 every 2 weeks Janjigian, ESMO 2011; Cancer Discovery 2014
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationHacia una mayor individualización clínica en el CPNM. J.M. Sánchez Torres H.U. Princesa, Madrid
Hacia una mayor individualización clínica en el CPNM J.M. Sánchez Torres H.U. Princesa, Madrid Lung cancer histologic subtypes NSCLC (80-85%) SCLC (15-20%) Squamous carcinoma (25 30%) Non-squamous carcinoma
More informationManagement of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center Rogerio Lilenbaum, MD Yale Cancer Center/Smilow Cancer Hospital EGFR Mutation
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationLung Cancer. Karen Reckamp, MD Medical Director, Clinical Research. Click to edit Master Presentation Date
Advances in Targeted Therapy for Lung Cancer Karen Reckamp, MD Medical Director, Clinical Research City of Hope Comprehensive Cancer Center Click to edit Master Presentation Date Disclosures Consultant
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationSolange Peters, MD-PhD Cancer Center, Lausanne Switzerland EGFR AND NSCLC
Solange Peters, MD-PhD Cancer Center, Lausanne Switzerland EGFR AND NSCLC Interactive Clinical Case History Maria José 1963 Since end 2010, progressive dyspnea Attends Emergency Room 02.01.2011 after 3
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationBest of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer
Best of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer Howard (Jack) West, M JackWestM@gmail.com @JackWestM Swedish Cancer Institute Seattle, WA Best of ASCO 2014 Seattle, WA Learning Objectives
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationBest of ASCO 2014 Lung
Best of ASCO 214 Lung Heather Wakelee, MD Associate Professor of Medicine, Oncology Stanford Cancer Institute Stanford, California USA Outline ALK: 82: 1st line crizotinib Profile 114 83: ASCEND ceritinib
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationCombinations of targeted therapies in oncology an industry view
Combinations of targeted therapies in oncology an industry view Dr Susan Galbraith SVP Head of Oncology imed AstraZeneca WIN 2014 Symposium 23-24 June Paris France Disclosures I am a full time employee
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationHandout Slides Metastasiertes Nicht- Kleinzelliges Bronchialkarzinom
Handout Slides Metastasiertes Nicht- Kleinzelliges Bronchialkarzinom 25. DESO Kurs 19.-21.2.215 Dr. Martin Früh Titel der Präsentation Abteilung für Onkologie und Hämatologie Kantonsspital St. Gallen 2
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationManagement of EGFR-mutant NSCLC. Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center
Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center Disclosures Research Funding: Merck, Novartis, AstraZeneca, Millenium Consulting: AbbVie,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationLa sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica?
La sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica? GRUPPO A Luca Toschi (former Vanesa Gregorc) Who are oncogene
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationTKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad
TKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad Dra Pilar Lianes Barragan Consorcio Sanitario del Maresme (Barcelona) Indice Epidemiología TKI en primera línea Eficacia
More informationIntroduction. Methods. Patient and study design
Original Article Continuation of gefitinib plus chemotherapy prolongs progressionfree survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER Strategic Approaches Sequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI Yi-Long Wu Guangdong
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationImproving Therapy for EGFR-Mutant Lung Cancers. Zosia Piotrowska, MD Instructor, Harvard Medical School Massachusetts General Hospital Cancer Center
Improving Therapy for EGFR-Mutant Lung Cancers Zosia Piotrowska, MD Instructor, Harvard Medical School Massachusetts General Hospital Cancer Center Disclosures- Zofia Piotrowska Consulting- AstraZeneca,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 15,10 15,30 Ca polmonare (never smokers): attualità e prospettive di ricerca Giulio Metro Ca polmonare (never smokers): attualità
More informationActivity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement.
Activity of osimertinib and the selective RET inhibitor in an EGFR-mutant patient with acquired RET rearrangement. Z Piotrowska 1, H Isozaki 1, JK Lennerz 1, S Digumarthy 1, JF Gainor 1, N Marcoux 1, M
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationIs advanced lung cancer becoming a chronic disease?
Is advanced lung cancer becoming a chronic disease? James Chung-Man HO ( 何重文 ) M.D. FRCP Associate Professor, The University of Hong Kong Honorary Consultant, Department of Medicine Specialist in Respiratory
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More information